Vanda Pharmaceuticals, Inc. (VNDA)
-NasdaqGM 8.38 
1.26(17.70%) May 24, 4:00PM EDT|After Hours
:
8.26 0.12 (1.43%) May 24, 6:27PM EDT
| Prev Close: | 7.12 |
|---|
| Open: | 7.22 |
|---|
| Bid: | 7.37 x 800 |
|---|
| Ask: | 8.37 x 700 |
|---|
| 1y Target Est: | 10.25 |
|---|
| Beta: | 1.63 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 7.11 - 8.75 |
|---|
| 52wk Range: | 2.92 - 8.75 |
|---|
| Volume: | 2,586,872 |
|---|
| Avg Vol (3m): | 385,355 |
|---|
| Market Cap: | 237.54M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.85 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Nasdaq stocks posting largest percentage increasesAP(Fri, May 24)
- 4 Healthcare Stock Stories For the Holiday Weekendat Wall St. Cheat Sheet(Fri, May 24)
- Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of MarylandPR Newswire(Thu, May 23)
- VANDA PHARMACEUTICALS INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Vanda Pharmaceuticals price target raised to $17 from $11 at Lazard Capitalat theflyonthewall.com(Fri, May 17)
- Vanda Pharmaceuticals price target raised to $17 from $11 at Lazard Capitaltheflyonthewall.com(Fri, May 17)
- VANDA PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Vanda Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- Vanda Pharmaceuticals Earnings: Here’s Why Shares are Up Nowat Wall St. Cheat Sheet(Thu, May 9)
- Vanda Pharmaceuticals Inc. Earnings Call scheduled for 10:00 am ET todayCCBN(Thu, May 9)
- Q1 2013 Vanda Pharmaceuticals Inc. Earnings Release - Before Market OpenCCBN(Thu, May 9)
- Vanda Pharmaceuticals Reports First Quarter 2013 ResultsPR Newswire(Thu, May 9)
- VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements anEDGAR Online(Thu, May 9)
- Vanda Pharmaceuticals: Here’s What Investors Need to Know Before Earningsat Wall St. Cheat Sheet(Wed, May 8)
- VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EEDGAR Online(Sun, Apr 28)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 6.18 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.91 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.22 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | -0.50 |
|---|
Business Summary
Vanda Pharmaceuticals Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders.
View More